Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.
The Neuroendocrine Tumors Drugs in Development market research report provides an overview of the Neuroendocrine tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine tumors and features dormant and discontinued projects.
What are the targets of the Neuroendocrine tumors pipeline drugs market?
Some of the targets of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor.
Neuroendocrine tumors pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the Neuroendocrine tumors pipeline drugs market?
Some of the mechanisms of action of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor.
Neuroendocrine tumors pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the Neuroendocrine tumors pipeline drugs market?
Some of the routes of administration in the Neuroendocrine tumors pipeline drugs market are oral, intravenous, subcutaneous, intravenous drip, intraarterial, intratumor, intrahepatic, intralesional, intramuscular, and intravesical.
Neuroendocrine tumors pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the Neuroendocrine tumors pipeline drugs market?
The molecule types in the Neuroendocrine tumors pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, oncolytic virus, peptide, cell therapy, gene-modified cell therapy, vaccine, biologic, and monoclonal antibody conjugated.
Neuroendocrine tumors pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the Neuroendocrine tumors pipeline drugs market?
Some of the key companies in the Neuroendocrine tumors pipeline drugs market are Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc.
Neuroendocrine tumors pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor |
| Mechanisms of Action | Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor |
| Routes of Administration | Oral, Intravenous, Subcutaneous, Intravenous Drip, Intraarterial, Intratumor, Intrahepatic, Intralesional, Intramuscular, and Intravesical |
| Molecule Types | Small Molecule, Monoclonal Antibody, Synthetic Peptide, Oncolytic Virus, Peptide, Cell Therapy, Gene-Modified Cell Therapy, Vaccine, Biologic, and Monoclonal Antibody Conjugated |
| Key Companies | Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc |
This report provides:
- A snapshot of the global therapeutic landscape of Neuroendocrine tumors.
- Reviews of pipeline therapeutics for Neuroendocrine tumors by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Key players involved in Neuroendocrine tumors therapeutics and enlists all their major and minor projects.
- Assessment of Neuroendocrine tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Neuroendocrine tumors.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine tumors.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Neuroendocrine tumors pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The targets of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2, Somatostatin Receptor, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2, Receptor Type Tyrosine Protein Kinase FLT3, Somatostatin Receptor Type 5, and Cells Expressing Somatostatin Receptor.
Some of the mechanisms of action of the Neuroendocrine tumors pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Somatostatin Receptor Agonist, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Somatostatin Receptor Type 2, Somatostatin Receptor Type 2 Agonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Somatostatin Receptor Type 5 Agonist, and Cytotoxic To Cells Expressing Somatostatin Receptor.
Some of the routes of administration in the Neuroendocrine tumors pipeline drugs market are oral, intravenous, subcutaneous, intravenous drip, intraarterial, intratumor, intrahepatic, intralesional, intramuscular, and intravesical.
The molecule types in the Neuroendocrine tumors pipeline drugs market are small molecule, monoclonal antibody, synthetic peptide, oncolytic virus, peptide, cell therapy, gene-modified cell therapy, vaccine, biologic, and monoclonal antibody conjugated.
Some of the key companies in the Neuroendocrine tumors pipeline drugs market are Ipsen SA, Exelixis Inc, Hutchison MediPharma Ltd, Pfizer Inc, Advanced Accelerator Applications SA, ASCIL Biopharm, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, and Chimerix Inc.
